Organ Transplant-Focused TransMedics Stock Soars, Solid Q3 Performance In Focus
Portfolio Pulse from Vandana Singh
TransMedics Group Inc reported Q3 revenues of $66.4 million, a 159% Y/Y increase, beating the consensus of $49.19 million. The increase was due to greater utilization of the company's NOP across all three OCS products and the addition of logistics and aviation revenue. The company reported a Q3 EPS loss of $(0.78), down from $(0.25) a year ago. TransMedics has updated its FY23 revenues guidance to $222 million-$230 million, compared to prior guidance of $180 million-$190 million.
November 07, 2023 | 4:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TransMedics reported strong Q3 revenues, beating consensus, but also reported a larger EPS loss compared to a year ago. The company has updated its FY23 revenues guidance to a higher range.
TransMedics reported strong Q3 revenues, which is a positive signal for investors. However, the company also reported a larger EPS loss compared to a year ago, which could be a concern. The updated FY23 revenues guidance to a higher range indicates the company's confidence in its future performance, which could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100